Elif Burcu BAL, Gülşah ALBAYRAK, Funda DEMİRTAŞ KORKMAZ, Emin Ümit BAĞRIAÇIK

Does memantine show chemopreventive effect against mice 4T1 breast tumor model?

Background/aim: Cancer cells express higher levels of N-methyl-d-aspartate (NMDA) receptor. In this study, we aimed to use memantine as a potential blocker to inhibit the action of the NMDA receptor in cancer cells in vivo in order to investigate the potential chemopreventive effect of memantine in 4T1 tumor-bearing mice. Materials and methods: To determine the potential chemopreventive effect of the compound, mice weights, tumor volumes, spleen IL-6, and tumor DNA methylation levels were investigated. A total of 26 Balb/c female mice were allocated into three groups. G1 (n = 6): tumor control group, G2 (n = 10): low dose (5mg/kg) memantine group, G3: high dose (10 mg/kg) memantine group (n = 10). G1 was inoculated with 4T1 cells without any memantine treatment. G2 and G3 were pretreated with 5 and 10 mg/kg memantine daily intraperitoneal (ip) injection (weekend off) for 10 days, respectively. Both G2 and G3 were subdivided into two groups as G2a (n = 4) and G3a (n = 4): tumor free groups and G2b (n = 6) and G3b (n = 6) tumor bearing groups. Results: Our results revealed that G3: high dose (10 mg/kg) memantine group, significantly (p = 0.0248) reduced the tumor volumes. We found that spleen IL-6 levels were significantly higher in memantine pretreated tumor free group p = 0.0204 ) We also found that high dose memantine treated tumor free group (G3a) has significantly lower genome-wide DNA methylation levels when compared to tumor control group (G1) p = 0.0012. Conclusion: To the best of our knowledge, it is the first study that highlights a potential chemopreventive effect of memantine in vivo in the mouse 4T1 breast tumor model. But further investigations should be carried out to explore the chemopreventive mechanism of action for memantine in cancer.

PDF

___

1. Alam S, Lingenfelter KS, Bender AM, Lindsley CW. Classics in chemical neuroscience: memantine. ACS Chemical Neuroscience 2017;8(9):1823–1829. doi:10.1021/ acschemneuro.7b00270
2. North WG, Liu F, Dragnev KH, Demidenko E. Small-cell lung cancer growth inhibition: synergism between NMDA receptor blockade and chemotherapy. Clinical Pharmacology: Advances and Applications 2019;11:15–23. doi: 10.2147/CPAA.S183885
3. Cacciatore I, Fornasari E, Marinelli L, Eusepi P, Ciulla M et al. Memantine-derived drugs as potential antitumor agents for the treatment of glioblastoma. European Journal of Pharmaceutical Sciences: official Journal of The European Federation for Pharmaceutical Sciences 2017;109:402–411. doi:10.1016/j.ejps.2017.08.030
4. Du S, Sung YS, Wey M, Wang Y, Alatrash N et al. Roles of N-methyl-d-aspartate receptors and d-amino acids in cancer cell viability. Molecular Biology Reports 2020;47(9):6749– 6758. doi:10.1007/s11033-020-05733-8
5. Miladinovic T, Nashed MG, Singh G. Overview of glutamatergic dysregulation in central pathologies. Biomolecules 2015;5(4):3112–3141. doi:10.3390/biom5043112
6. Chae YK, Arya A, Malecek MK, Shin DS, Carneiro B et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget 2016;7(26):40767–40780. doi:10.18632/ oncotarget.8194
7. Shah RR, Stonier PD. Repurposing old drugs in oncology: opportunities with clinical and regulatory challenges ahead. Journal of Clinical Pharmacy and Therapeutics 2019;44(1):6– 22. doi:10.1111/jcpt.12759
8. Heckman-Stoddard BM, Gandini S, Puntoni M, Dunn BK, Decensi A et al. Repurposing old drugs to chemoprevention: the case of metformin. Seminars in Oncology 2016;43(1):123– 133. doi:10.1053/j.seminoncol.2015.09.009
9. North WG, Gao G, Memoli VA, Pang RH, Lynch L. Breast cancer expresses functional NMDA receptors. Breast Cancer Research and Treatment 2010;122(2):307-14. doi:10.1007/s10549-009- 0556-1
10. Seifabadi S, Vaseghi G, Javanmard SH, Omidi E, Tajadini M et al. The cytotoxic effect of memantine and its effect on cytoskeletal proteins expression in metastatic breast cancer cell line. Iranian Journal of Basic Medical Sciences 2017;20(1):41–45. doi:10.22038/ijbms.2017.8091
11. Yoon WS, Yeom MY, Kang ES, Chung YA, Chung DS et al. Memantine induces NMDAR1-mediated autophagic cell death in malignant glioma cells. Journal of Korean Neurosurgical Society 2017;60(2):130–137. doi:10.3340/jkns.2016.0101.006
12. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-Oncology 2013;15(10):1429–1437. doi:10.1093/neuonc/not114
13. Jafari A, Siavashpour Z, Houshyari M. An updated review on memantine efficacy in reducing cognitive dysfunction of whole-brain irradiation for adult patients with brain metastasis. International Journal of Cancer Management 2021;14(4): e111966. doi: 10.5812/ijcm.111966
14. Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA et al. Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer 2019;125(3):424–433. doi:10.1002/ cncr.31811
15. Brown KC, Lau JK, Dom AM, Witte TR, Luo H et al. MG624, an α7-nAChR antagonist, inhibits angiogenesis via the Egr-1/ FGF2 pathway. Angiogenesis 2012;15(1):99-114. doi: 10.1007/ s10456-011-9246-9
16. Lowinus T, Heidel FH, Bose T, Nimmagadda SC, Schnöder T et al. Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling. Cell Communication and Signaling:CCS 2019;17(1):5. doi:10.1186/s12964-018- 0317-z
17. Albayrak G, Korkmaz FD, Bali EB, Bagriacik EU. Antitumorigenic effect of memantine via interfering glutamate metabolism in mouse 4T1 breast tumor model. Anti-Cancer Agents in Medicinal Chemistry 2021;21(12):1575-1580. doi: 10.2174/09 29867327666201020155733
18. Albayrak G, Demirtas Korkmaz F. Memantine shifts cancer cell metabolism via AMPK1/2 mediated energetic switch in A549 lung cancer cells. EXCLI Journal 2021; 20:223-231. doi:10.17179/excli2020-2890
19. Szegedi V, Juhász G, Parsons CG, Budai D. In vivo evidence for functional NMDA receptor blockade by memantine in rat hippocampal neurons. Journal of Neural Transmission 2010;117(10):1189-1194. doi: 10.1007/s00702-010-0471-y
20. Beconi MG, Howland D, Park L, Lyons K, Giuliano J et al. Pharmacokinetics of memantine in rats and mice. PLOS Currents 2011;3:RRN1291. doi:10.1371/currents.RRN1291
21. Aggarwal S, Verma SS, Aggarwal S, Gupta SC. Drug repurposing for breast cancer therapy: old weapon for new battle. Seminars in Cancer Biology 2021;68:8-20. doi:10.1016/j. semcancer.2019.09.012
22. Nigjeh SE, Yeap SK, Nordin N, Rahman H, Rosli R. In vivo antitumor effects of citral on 4t1 breast cancer cells via ınduction of apoptosis and downregulation of aldehyde dehydrogenase activity. Molecules 2019;24(18):3241. doi:10.3390/ molecules24183241
23. Costa B, Amorim I, Gärtner F, Vale N. Understanding breast cancer: from conventional therapies to repurposed drugs. European Journal of Pharmaceutical Sciences: Official Journal of The European Federation for Pharmaceutical Sciences 2020;151:105401. doi:10.1016/j.ejps.2020.105401
24. Varghese E, Samuel SM, Líšková A, Samec M, Kubatka P et al. Targeting glucose metabolism to overcome resistance to anticancer chemotherapy in breast cancer. Cancers 2020; 12(8):2252. doi:10.3390/cancers12082252
25. Dienz O, Rincon M. The effects of IL-6 on CD4 T cell responses. Clinical Immunology 2009;130(1):27-33. doi:10.1016/j. clim.2008.08.018
26. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harbor Perspectives in Biology 2014;6(10):a016295. doi: 10.1101/cshperspect.a016295
27. Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment. Seminars in Immunology 2014;26(1):38-47. doi:10.1016/j.smim.2014.01.008
28. Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harbor Perspectives in Biology 2016;8(9):a019505. doi: 10.1101/cshperspect.a019505
29. Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. Science 2017;357(6348):eaal2380. doi:10.1126/science.aal2380
30. Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM et al. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Internal Medicine 2016;176(12):1826-1833. doi: 10.1001/ jamainternmed.2016.6008